<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>PromptGenix – Commercialization Plan (Phase I → Phase II)</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="description" content="PromptGenix SBIR Phase I→II commercialization plan: customers, value proposition, business model, competitive landscape, go-to-market, and de-risking path."/>

  <style>
    * { box-sizing: border-box; }
    body{
      margin:0;
      font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",sans-serif;
      background:#020617;
      color:#e5e7eb;
      line-height:1.5;
    }
    a{ color:inherit; text-decoration:none; }
    .page{ min-height:100vh; display:flex; flex-direction:column; }

    header{
      position:sticky; top:0; z-index:30;
      backdrop-filter: blur(14px);
      background: rgba(15, 23, 42, 0.92);
      border-bottom: 1px solid rgba(148, 163, 184, 0.3);
    }
    .nav{
      max-width:1120px; margin:0 auto; padding:14px 20px;
      display:flex; align-items:center; justify-content:space-between; gap:18px;
    }
    .nav-left{ display:flex; align-items:center; gap:12px; }
    .logo-dot{
      width:28px; height:28px; border-radius:999px;
      background: radial-gradient(circle at 0 0,#38bdf8,#8b5cf6);
      box-shadow:0 0 18px rgba(56,189,248,.7);
    }
    .brand{ font-size:1.1rem; font-weight:650; letter-spacing:.04em; }
    .subbrand{ font-size:.72rem; color:#9ca3af; margin-top:2px; }

    .nav-links{ display:flex; gap:10px; flex-wrap:wrap; justify-content:flex-end; }
    .nav-links a{
      font-size:.88rem; color:#9ca3af;
      padding:6px 10px; border-radius:999px;
      border:1px solid rgba(148,163,184,0.18);
      background: rgba(2,6,23,0.25);
    }
    .nav-links a:hover{
      color:#e5e7eb;
      background: rgba(148,163,184,0.18);
      border-color: rgba(148,163,184,0.35);
    }
    .nav-links a.active{
      color:#e5e7eb;
      background: rgba(148,163,184,0.18);
      border-color: rgba(148,163,184,0.55);
    }

    main{ flex:1; }

    .section{
      max-width: 1120px;
      margin: 0 auto;
      padding: 28px 20px;
    }

    .topline{
      display:flex; flex-wrap:wrap; gap:10px;
      align-items:flex-end; justify-content:space-between;
      padding-top: 16px;
      margin-bottom: 14px;
    }
    .doc-title{
      font-size: 1.35rem;
      font-weight: 820;
      color:#f9fafb;
      margin: 0;
    }
    .meta{
      font-size:.78rem;
      color:#9ca3af;
    }

    .kicker{
      font-size: .78rem;
      text-transform: uppercase;
      letter-spacing: .18em;
      color: #a5b4fc;
      margin: 18px 0 6px;
    }

    h2{
      font-size: 1.15rem;
      font-weight: 760;
      color:#f9fafb;
      margin: 10px 0 8px;
    }

    p{
      margin: 0 0 10px;
      font-size: .95rem;
      color:#d1d5db;
    }

    .grid-2{
      display:grid;
      grid-template-columns: minmax(0,1fr) minmax(0,1fr);
      gap:18px;
      margin-top: 12px;
      align-items:start;
    }

    .card{
      border-radius: 16px;
      padding: 14px 16px;
      background: rgba(15,23,42,0.84);
      border: 1px solid rgba(148,163,184,0.28);
      box-shadow: 0 18px 45px rgba(15,23,42,0.55);
    }

    .card h3{
      margin: 0 0 8px;
      font-size: .95rem;
      letter-spacing: .14em;
      text-transform: uppercase;
      color:#a5b4fc;
    }

    ul{
      margin: 6px 0 0;
      padding-left: 1.1rem;
      color:#d1d5db;
      font-size: .94rem;
    }
    li{ margin-bottom: 6px; }
    li strong{ color:#e5e7eb; }

    .pill-row{ display:flex; flex-wrap:wrap; gap:8px; margin-top:10px; }
    .pill{
      font-size:.74rem;
      padding: 5px 9px;
      border-radius: 999px;
      border: 1px solid rgba(129,140,248,0.45);
      background: rgba(2,6,23,0.25);
      color:#c7d2fe;
    }

    .callout{
      border-radius: 14px;
      padding: 12px 14px;
      border: 1px dashed rgba(148,163,184,0.5);
      background: rgba(15,23,42,0.75);
      font-size: .92rem;
      color:#e5e7eb;
      margin-top: 12px;
    }
    .callout strong{ color:#22c55e; }

    /* Table */
    .table{
      width:100%;
      border-collapse: collapse;
      margin-top: 10px;
      overflow:hidden;
      border-radius: 14px;
      border: 1px solid rgba(148,163,184,0.28);
      background: rgba(15,23,42,0.6);
    }
    .table th, .table td{
      padding: 12px 12px;
      border-bottom: 1px solid rgba(148,163,184,0.18);
      vertical-align: top;
      font-size: .95rem;
      color:#e5e7eb;
    }
    .table th{
      font-size: .82rem;
      text-transform: uppercase;
      letter-spacing: .14em;
      color:#a5b4fc;
      background: rgba(2,6,23,0.35);
    }

    /* “Equation” chip (commercial page: short, reviewer-friendly) */
    .mathline{
      font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono","Courier New", monospace;
      font-size: .90rem;
      color:#e5e7eb;
      border: 1px solid rgba(148,163,184,0.28);
      background: rgba(2,6,23,0.30);
      border-radius: 12px;
      padding: 10px 12px;
      margin-top: 10px;
      overflow-x:auto;
      white-space: nowrap;
    }
    .mathline strong{ color:#22c55e; }

    footer{
      border-top:1px solid rgba(31,41,55,0.9);
      padding:16px;
      font-size:.78rem;
      color:#6b7280;
      text-align:center;
    }

    @media (max-width: 920px){
      .grid-2{ grid-template-columns: minmax(0,1fr); }
    }

    @media print {
      header, footer { display: none !important; }
      body { background:#fff !important; color:#111 !important; }
      p, li { color:#111 !important; }
      h1, h2, h3 { color:#111 !important; }
      * { box-shadow: none !important; }
      @page { size: Letter; margin: 0.5in; }
      .section { max-width: 100% !important; padding: 0 !important; }
      .card, .callout, .mathline, .table { background:#fff !important; color:#111 !important; }
      .mathline{ border:1px solid #111 !important; }
      .table th, .table td{ color:#111 !important; border-bottom:1px solid #bbb !important; }
      .table th{ background:#f3f4f6 !important; }
    }
  </style>
</head>

<body>
<div class="page">
  <header>
    <div class="nav">
      <div class="nav-left">
        <div class="logo-dot"></div>
        <div>
          <div class="brand">PromptGenix</div>
          <div class="subbrand">SBIR Portal</div>
        </div>
      </div>
      <nav class="nav-links">
        <a href="index.html">Portal</a>
        <a href="sbir.html">SBIR</a>
        <a href="aims.html">Aims</a>
        <a href="approach.html">Approach</a>
        <a href="commercialization.html" class="active">Commercialization</a>
        <a href="facilities.html">Facilities</a>
        <a href="team.html">Team</a>
        <a href="use-cases.html">Use Cases</a>
      </nav>
    </div>
  </header>

  <main>
    <section class="section">
      <div class="topline">
        <h1 class="doc-title">Commercialization Plan (Phase I → Phase II)</h1>
        <div class="meta">
          PromptGenix LLC &middot; Contact: dohoon.kim1@icloud.com &middot; promptgenix.org
        </div>
      </div>

      <div class="kicker">Positioning</div>
      <h2>Evidence-weighted hypothesis intelligence for faster, more transparent scientific decisions.</h2>
      <p>
        PromptGenix commercializes a hypothesis intelligence platform that integrates public biomedical datasets and scientific literature to produce
        <strong>ranked, testable hypotheses</strong> with <strong>probabilistic confidence</strong>, explicit evidence links, and actionable next-step recommendations.
        The platform is designed to <strong>support</strong> (not replace) human scientific judgment by making evidence integration faster, reproducible, and reviewer-friendly.
      </p>

      <div class="callout">
        <strong>Key design choice:</strong> LLMs do not set confidence. Confidence is computed by an evidence-weighted Bayesian decision engine;
        the LLM only explains rankings using linked evidence objects and citations (supporting or conflicting), with uncertainty explicitly stated.
      </div>

      <div class="grid-2">
        <div class="card">
          <h3>Primary customers</h3>
          <ul>
            <li><strong>NIH-funded academic labs</strong> in immunology, infectious disease, vaccine/HIV research.</li>
            <li><strong>Government research groups</strong> needing reproducible, auditable decision support (secure/on-prem options).</li>
            <li><strong>Biotech & translational teams</strong> prioritizing targets/biomarkers under time constraints.</li>
            <li><strong>CROs & core facilities</strong> supporting multiple projects with standardized, traceable deliverables.</li>
          </ul>
          <div class="pill-row">
            <span class="pill">Academic</span>
            <span class="pill">Government</span>
            <span class="pill">Biotech</span>
            <span class="pill">CRO / Core</span>
          </div>
        </div>

        <div class="card">
          <h3>Value proposition</h3>
          <ul>
            <li><strong>Faster hypothesis-to-experiment:</strong> compress synthesis from weeks to days (or &lt;24h for accession-driven runs).</li>
            <li><strong>Confidence with uncertainty:</strong> probabilistic ranking + credible intervals + evidence coverage.</li>
            <li><strong>Traceability:</strong> every hypothesis links to evidence objects and cited sources (supporting vs. conflicting).</li>
            <li><strong>Reproducibility:</strong> versioned configs, deterministic reruns, exportable artifacts.</li>
            <li><strong>Flexible deployment:</strong> local workstation, secure VPC, or on-prem for sensitive settings (Phase II+).</li>
          </ul>

          <div class="mathline" aria-label="Bayesian summary equation">
            <strong>Bayesian summary:</strong>
            Posterior confidence = P(H|E) ∝ P(H) × Πᵢ P(Eᵢ|H), reported with CrI + support/conflict coverage.
          </div>
        </div>
      </div>

      <div class="kicker">Business model</div>
      <div class="grid-2">
        <div class="card">
          <h3>Revenue streams</h3>
          <ul>
            <li><strong>SaaS subscriptions (Phase II):</strong> seat-based tiers for labs and core facilities.</li>
            <li><strong>Enterprise / Gov deployments:</strong> secure VPC or on-prem licensing + support.</li>
            <li><strong>Services-to-product bridge:</strong> limited pilot engagements that convert into recurring subscriptions.</li>
          </ul>
          <div class="callout">
            <strong>Commercial focus:</strong> sell the decision product (ranked hypotheses + uncertainty + traceability), not “data analysis as a service.”
          </div>
        </div>

        <div class="card">
          <h3>Pricing anchors (Phase II targets)</h3>
          <ul>
            <li><strong>Lab tier:</strong> $499–$1,499 / month (small team, limited runs, standard reports).</li>
            <li><strong>Core/CRO tier:</strong> $2,500–$7,500 / month (multi-project, higher throughput, audit trail).</li>
            <li><strong>Enterprise:</strong> custom (secure deployment + integrations + SLAs).</li>
          </ul>
          <p class="meta" style="margin-top:10px;">
            Pricing will be validated with pilot demand and willingness-to-pay during Phase I / early Phase II.
          </p>
        </div>
      </div>

      <div class="kicker">Competitive landscape</div>
      <h2>Differentiation vs. point tools, workflow frameworks, and general-purpose AI assistants.</h2>

      <table class="table" aria-label="Competitive landscape table">
        <thead>
          <tr>
            <th style="width:22%;">Category</th>
            <th style="width:33%;">Strengths</th>
            <th style="width:45%;">PromptGenix differentiation</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td><strong>Point tools</strong><br/><span class="meta">Seurat, GSEA, FlowJo, etc.</span></td>
            <td>Best-in-class for specific steps; familiar to labs.</td>
            <td>Converts outputs into standardized evidence objects and produces ranked hypotheses with uncertainty, reducing manual synthesis and “glue code” across tools.</td>
          </tr>
          <tr>
            <td><strong>Workflow scripting</strong><br/><span class="meta">custom pipelines / notebooks</span></td>
            <td>Flexible; tailored to a lab’s preferences.</td>
            <td>Productized, maintainable engine with deterministic configs and reusable templates; easier onboarding and consistent QA/traceability.</td>
          </tr>
          <tr>
            <td><strong>Generic LLM assistants</strong></td>
            <td>Fast writing/summarization; broad coverage.</td>
            <td>Evidence-weighted inference + “no evidence, no claim” guardrails; LLM used for explanation only, constrained by evidence links, citations, and uncertainty flags.</td>
          </tr>
        </tbody>
      </table>

      <div class="kicker">Go-to-market</div>
      <div class="grid-2">
        <div class="card">
          <h3>Initial channels (Phase I → II)</h3>
          <ul>
            <li><strong>Pilot studies:</strong> 2–3 public-data demonstrations packaged as reviewer-ready reports.</li>
            <li><strong>Academic adoption:</strong> early adopters via immunology/infectious disease communities and core facilities.</li>
            <li><strong>Government pathway:</strong> reproducibility + auditability positioning for secure deployments.</li>
            <li><strong>Content funnel:</strong> publish non-sensitive demos and technical notes using public datasets.</li>
          </ul>
        </div>

        <div class="card">
          <h3>De-risking milestones</h3>
          <ul>
            <li><strong>Phase I:</strong> deterministic evidence objects, posterior confidence outputs, traceable reports, and usability KPIs.</li>
            <li><strong>Phase II:</strong> scale to multi-dataset/multi-site cohorts, secure deployment options, UI automation, integrations.</li>
            <li><strong>Commercial traction:</strong> convert pilots into paid subscriptions; expand to CRO/core facility customers.</li>
          </ul>
          <div class="callout">
            <strong>Buyer confidence trigger:</strong> consistent ranking rationale across reruns + explicit support/conflict coverage + calibrated uncertainty.
          </div>
        </div>
      </div>

      <div class="kicker">Near-term KPIs</div>
      <div class="grid-2">
        <div class="card">
          <h3>Product KPIs</h3>
          <ul>
            <li><strong>Time-to-report:</strong> &lt;24h for accession-driven runs (dataset-dependent).</li>
            <li><strong>Reproducibility:</strong> deterministic reruns with versioned artifacts and checksums.</li>
            <li><strong>Traceability:</strong> every hypothesis links to evidence objects + cited sources.</li>
            <li><strong>Uncertainty labeling:</strong> credible intervals + support/conflict/missing flags.</li>
          </ul>
        </div>
        <div class="card">
          <h3>Commercial KPIs</h3>
          <ul>
            <li><strong>Pilot conversions:</strong> pilot → paid subscription conversion rate.</li>
            <li><strong>Retention:</strong> repeat use across projects and cohorts.</li>
            <li><strong>Willingness-to-pay:</strong> pricing validation by segment (lab vs core/CRO vs enterprise).</li>
            <li><strong>Security readiness:</strong> roadmap progress toward VPC/on-prem deployments (Phase II).</li>
          </ul>
        </div>
      </div>

      <div class="callout">
        <strong>Phase I → Phase II bridge:</strong> Phase I proves feasibility and reviewer trust (traceable Bayesian confidence + deterministic artifacts).
        Phase II productizes secure deployment, scales cohort complexity, and expands integrations to drive recurring revenue.
      </div>

    </section>
  </main>

  <footer>
    PromptGenix &middot; SBIR Portal &middot;
    <a href="mailto:dohoon.kim1@icloud.com">dohoon.kim1@icloud.com</a>
  </footer>
</div>
</body>
</html>
